SHOCK ALERT! Novavax COVID vaccine exposes victims to extremely dangerous heart inflammation

2 Min Read

SHOCK ALERT! Novavax COVID vaccine exposes victims to extremely dangerous heart inflammation

On Friday, FDA workers expressed concerns about a possible risk of heart inflammation from Novavax Inc’s vaccine (NVAX.O). The company’s data showed that the vaccine was effective in reducing the risk of mild-to-severe COVID-19.

Within 20 days after vaccination, four cases of myocarditis were discovered in the firm’s nearly 30,000 patient trials. Myocarditis is a kind of heart inflammation linked with mRNA vaccines. After receiving a placebo, one participant in the study suffered from myocarditis.

According to the U.S. Food and Drug Administration, there is a high risk of heart inflammation after Novavax COVID immunization.

“These events raise the concern for a causal association with this vaccine, similar to the association documented with mRNA COVID19 vaccines,” On Friday, The FDA staff wrote in briefing documents.

Novavax said there were more events of myocarditis in its clinical trial. “within the range of expected background cases.”

Novavax has announced that its protein-based shot will help to encourage immunization among persons who have been hesitant to get vaccinated, and it has started a media campaign.

“Despite the wide availability of authorized or approved vaccines, the SARS-CoV-2 pandemic is not well controlled in the U.S. … there remains a desire for vaccines that have been developed using well-understood technology platforms,” it said.

Before the Omicron and Delta variants became dominant strains, the FDA reviewed data from Novavax’s trial.

“Based on the efficacy estimate in the clinical trial of this vaccine, it is more likely than not that the vaccine will provide some meaningful level of protection against COVID-19 due to Omicron, in particular against more severe disease,” FDA staff said…

The FDA’s advisers will use the briefing document and staff’s notes to make a decision on whether or not to recommend the vaccine on Tuesday. Generally, outside experts follow the recommendations of the FDA. However, this is not always the case. A study that looked at around 30,000 adults in the United States and Mexico found that the vaccine was 90.4% effective.

Share this Article
Leave a comment